CD38 as a pan-hematologic target for chimeric antigen receptor T cells.

Blood Adv · 2023 · PMC10440474 · PMID 37171449

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

Treatment with CART-38 and with CART-123 also significantly prolonged survival compared with UTD-treated animals with a nonsignificant trend to improved survival in the CART-123 vs CART-38 cohort in this model ( Figure 3 C).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.